EGEugene W. Gerner

Eugene W. Gerner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eugene W. Gerner has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Natalia A. Ignatenko

    Arizona Cancer Center, 1515 N Campbell Ave, P.O. Box 245024, Tucson, AZ 85724, USA

    4 shared publications
  • David E. Stringer

    The Arizona Cancer Center, University of Arizona, Tucson, Arizona

    3 shared publications
  • Frank L. Meyskens

    ‡Chao Family Comprehensive Cancer Center and Departments of Medicine and Epidemiology, University of California, Irvine, CA 92868 U.S.A.

    3 shared publications
  • Takeshi Uemura

    Arizona Cancer Center, University of Arizona, Tucson, AZ, USA

    3 shared publications
  • Nathaniel S. Rial

    Department of Internal Medicine, The University of Arizona, Tucson, AZ 85724, USA

    2 shared publications
  • Peter Lance

    Department of Medicine, University of Arizona, Tucson, AZ

    2 shared publications

Latest Publications

  • Get the Fat Out!

    by Natalia A. Ignatenko, Eugene W. Gerner

    Obesity is associated with increased risk of a number of cancers in humans, but the mechanism(s) responsible for these associations have not been established. It is estimated that 68% of adults are overweight or obese and that obesity may be causative in 4% to 7% of cancers in the United States. Several hypotheses have been put forward to explain the association between obesity and cancer including adipose-directed signaling (e.g., mTOR, AMPK), production of factors (e.g., insulin growth factor 1, fibroblast growth factor 1, and/or chronic inflammation associated with obesity. Huffman and colleagues used surgical methods to determine if visceral fat was causally related to intestinal tumorigenesis in the Apc1638/N+ mouse in a manner independent of confounding factors such as caloric restriction. They found that caloric restriction could extend survival in both male and female Apc1638/N+ mice but found that surgical removal of visceral fat was only effective in reducing macroadenomas in females. The results of this study do not identify the specific mechanism of association between visceral fat and intestinal carcinogenesis in female mice but do support the rationale for future cancer prevention trials that evaluate pharmacologic and behavioral strategies to reduce abdominal obesity in humans. Cancer Prev Res; 6(3); 161–4. ©2013 AACR.


  • Open Access

    Caveolin‐1 is a novel regulator of K‐RAS‐dependent migration in colon carcinogenesis

    by Upal K. Basu Roy, Rebecca S. Henkhaus, Fotios Loupakis, Chiara Cremolini, Eugene W. Gerner, Natalia A. Ignatenko

    Caveolin‐1 is an essential component of membrane caveolae. It is an important regulator of cellular processes such as signal transduction and endocytosis. We report here, for the first time, that caveolin‐1 is a target of the K‐RAS oncogene in colon carcinogenesis. Caveolin‐1 is induced in colon cancer cells and in human colon tumor samples, in response to K‐RAS activating mutations. An activated K‐RAS oncogene transcriptionally induces caveolin‐1 expression in human colon cancer cells and this effect is not restricted to the type of activating K‐RAS mutation. Inhibition of the P‐I3 Kinase‐AKT pathway, but not the ERK MAPK pathway, both important K‐RAS effectors, leads to a decrease in caveolin‐1 expression indicating that the AKT pathway is involved in caveolin‐1 expression in response to an activated K‐RAS. Increased AKT signaling induces caveolin‐1 expression by increasing the activity of the transcription factor, Sp1. Interestingly; caveolin‐1 depletion alters K‐RAS‐dependent signaling by decreasing Grb2‐SOS activity. Consistent with these finding, caveolin‐1‐depleted cells shows decreased migration in vitro. However, caveolin‐1 overexpression by itself does not increase migration whereas an activated Src can increase migration in a caveolin‐1‐dependent manner. This increased migration is highly dependent on the RhoA GTPase, indicating that an activated K‐RAS modulates migration in part via caveolin‐1 induction, and increasing RhoA activity via phospho‐caveolin‐1. Our findings indicate that K‐RAS regulates both caveolin‐1 expression and other factors affecting caveolin‐1 functions in colon cancer‐derived cell migration.


  • Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer

    by Nathaniel S Rial, Jason A Zell, Alfred M Cohen, Eugene W Gerner

    (2012). Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer. Expert Review of Gastroenterology & Hepatology: Vol. 6, No. 4, pp. 507-517.


  • Polyamine Transport Systems in Mammalian Cells and Tissues

    by Takeshi Uemura, Eugene W. Gerner

    Polyamine transport plays an important role in the homeostatic regulation of the polyamine levels. In animals, dietary polyamines are absorbed efficiently in the intestinal tract. In the colon, luminal bacterial derived polyamines are important contributors to cellular polyamine contents. Polyamine transport involves unique uptake and export mechanisms. The amino acid transporter SLC3A2 acts as a polyamine exporter in colon cancer-derived cells. Polyamine uptake is mediated by caveolin-1 dependent ­endocytosis. The K-RAS oncogene signals increased polyamine uptake and decreased polyamine export. Here, we describe the methods of polyamine transport analysis in the colon and the small intestine using ­membrane vesicles, culture cells, and mouse models.


  • Targeting Polyamines and Inflammation for Cancer Prevention

    by Naveen Babbar, Eugene W. Gerner

    Increased polyamine synthesis and inflammation have long been associated with intraepithelial neoplasia, which are risk factors for cancer development in humans. Targeting polyamine metabolism (by use of polyamine synthesis inhibitors or polyamine catabolism activators) and inflammation (by use of nonsteroidal anti-inflammatory drugs) has been studied for many cancers, including colon, prostate, and skin. Genetic epidemiology results indicate that a genetic variant associated with the expression of a polyamine biosynthetic gene is associated with risk of colon and prostate cancers. A clinical trial of difluoromethylornithine (DFMO), a selective inhibitor of polyamine synthesis, showed that the 1 year treatment duration reduced prostate volume and serum prostate-specific antigen doubling time in men with a family history of prostate cancer. A second, clinical trial of DFMO in combination with sulindac, a NSAID in patients with prior colon polyps found that the 3-year treatment was associated with a 70% reduction of all, and over a 90% reduction of advanced and/or multiple metachronous colon adenomas. In this chapter, we discuss that similar combination prevention strategies of targeting polyamines and inflammation can be effective in reducing risk factors associated with the development of human cancers.


  • Polyamine transport is mediated by both endocytic and solute carrier transport mechanisms in the gastrointestinal tract

    by Takeshi Uemura, David E. Stringer, Karen A. Blohm-Mangone, Eugene W. Gerner

    The polyamines spermidine and spermine, and their precursor putrescine, are required for cell growth and cellular functions. The high levels of tissue polyamines are implicated in carcinogenesis. The major sources of exogenous polyamines are diet and intestinal luminal bacteria in gastrointestinal (GI) tissues. Both endocytic and solute carrier-dependent mechanisms have been described for polyamine uptake. Knocking down of caveolin-1 protein increased polyamine uptake in colon cancer-derived HCT116 cells. Dietary supplied putrescine was accumulated in GI tissues and liver in caveolin-1 knockout mice more than wild-type mice. Knocking out of nitric oxide synthase (NOS2), which has been implicated in the release of exogenous polyamines from internalized vesicles, abolished the accumulation of dietary putrescine in GI tissues. Under conditions of reduced endogenous tissue putrescine contents, caused by treatment with the polyamine synthesis inhibitor difluoromethylornithine (DFMO), small intestinal and colonic mucosal polyamine contents increased with dietary putrescine levels, even in mice lacking NOS2. Knocking down the solute carrier transporter SLC3A2 in HCT116-derived Hkh2 cells reduced the accumulation of exogenous putrescine and total polyamine contents in DFMO treated cells, relative to non-DFMO-treated cells. These data demonstrate that exogenous putrescine is transported into GI tissues by caveolin-1- and NOS2-dependent mechanisms, but that the solute carrier transporter SLC3A2 can function bidirectionally to import putrescine under conditions of low tissue polyamines.


  • Open Access

    Cancer Chemoprevention Locks onto a New Polyamine Metabolic Target

    by Eugene W. Gerner

    Ornithine decarboxylase has a relatively long history as a target for cancer chemoprevention and chemotherapy. Plym Forshell et al. report new evidence (beginning on p. 140 in this issue of the journal) indicating that spermidine synthase, a fellow enzyme of ornithine decarboxylase in polyamine metabolism, is transactivated in part by the MYC gene and is a potential target for chemoprevention of B-cell lymphomas. Cancer Prev Res; (3)2; 125–7


  • Open Access

    Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention

    by Nathaniel S. Rial, Frank L. Meyskens, Eugene W. Gerner

    Combination chemoprevention for cancer was proposed a quarter of a century ago, but has not been implemented in standard medical practice owing to limited efficacy and toxicity. Recent trials have targeted inflammation and polyamine biosynthesis, both of which are increased in carcinogenesis. Preclinical studies have demonstrated that DFMO (difluoromethylornithine), an irreversible inhibitor of ODC (ornithine decarboxylase) which is the first enzyme in polyamine biosynthesis, combined with NSAIDs (non-steroidal anti-inflammatory drugs) suppresses colorectal carcinogenesis in murine models. The preclinical rationale for combination chemoprevention with DFMO and the NSAID sulindac, was strengthened by the observation that a SNP (single nucleotide polymorphism) in the ODC promoter was prognostic for adenoma recurrence in patients with prior sporadic colon polyps and predicted reduced risk of adenoma in those patients taking aspirin. Recent results from a phase III clinical trial showed a dramatic reduction in metachronous adenoma number, size and grade. Combination chemoprevention with DFMO and sulindac was not associated with any serious toxicity. A non-significant trend in subclinical ototoxicity was detected by quantitative audiology in a subset of patients identified by a genetic marker. These preclinical, translational and clinical data provide compelling evidence for the efficacy of combination chemoprevention. DFMO and sulindac is a rational strategy for the prevention of metachronous adenomas, especially in patients with significant risk for colorectal cancer. Toxicities from this combination may be limited to subsets of patients identified by either past medical history or clinical tests.


  • Current concepts in colorectal cancer prevention

    by Patricia A Thompson, Eugene W Gerner

    (2009). Current concepts in colorectal cancer prevention. Expert Review of Gastroenterology & Hepatology: Vol. 3, No. 4, pp. 369-382.